BMS’ ‘CAR-T in a pill’ multiple myeloma drug has strong early showing at ASCO
Data for the drug, CC-92480, showed an overall response rate of more than 54% when given at the recommended Phase II dose in 11 heavily pretreated patients. The drug is part of a new class known as CELMoD agents.